Tofacitinib Citrate

Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety and efficacy, today announced that it is extending its human tissue platform beyond toxicology, the core of its business today, with efficacy testing services built on NAMkind™ disease models of the liver and intestine. The disease models are built with cells from patient donors, so they carry features of the disease itself. Drug developers can measure whether a candidate acts on those disease features in human tissue before it enters clinical trials. VivoSim offers efficacy testing alongside toxicology on its liver and gastrointestinal (GI) models. The move builds on demonstrated disease model excellence already demonstrated. Its intestinal efficacy platform, built in part from cells of patients with ulcerative colitis or Crohn’s disease, received a “Poster of Distinction” award at Digestive Disease Week in May 2025, in work showing that the platform responds to clinically used therapeutics. VivoSim has also used its human disease models to identify new molecular targets that drive inflammatory bowel disease (IBD) and to explore how known drugs act. Lack of efficacy is the most common reason drug candidates fail in clinical trials. In an analysis of more than 28,000 clinical trials stopped before reaching their endpoints, more than twice as many were stopped for negative results or lack of efficacy as for safety (Razuvayevskaya et al., Nature Genetics, 2024). “Toxicology is the core of our business today, and it will remain a core service,” said Keith Murphy, Executive Chairman of VivoSim Labs. “Our customers often need help with whether a candidate is likely to work, because that is where many drugs fall short in the clinic. Disease models let us address that question on the same human tissue platform we already use for safety, but leveraging patient-derived diseased cell sources so a customer can learn more before committing a program to clinical trials. We believe disease models could more than double our addressable market.” NAMkind™ Disease Models Liver (MASH): The NAMkind™ MASH disease model co-cultures healthy human liver cells with stellate, Kupffer, and endothelial cells from a donor with metabolic dysfunction-associated steatohepatitis (MASH), producing steatotic tissue with fibrosis. Compounds are dosed repeatedly over 14 or 21 days, with readouts for fibrosis and liver function. Cell-health markers measured in the same study separate an anti-fibrotic effect from cell damage. Intestine (IBD): The NAMkind™ IBD disease model is built from colon and small-intestine organoids derived from donors with ulcerative colitis and Crohn’s disease, with twelve donors currently available. It measures barrier integrity, inflammation, and fibrosis in the same well and reports results donor by donor. A healthy tissue comparator arm is available. Pharmacodynamic (PD) & Target Biomarker Profiling: The platform evaluates target engagement, gene expression panels, cytokine profiling, extracellular matrix turnover markers, and other relevant biomarkers across donor tissues, enabling sponsors to map mechanism-of-action and dose-response relationships alongside functional efficacy readouts. In both models, each study runs the client’s compound alongside an approved or clinically validated reference compound in the same donor tissue, such as resmetirom in the MASH model or tofacitinib or upadacitinib in the IBD model. In results VivoSim has published for the IBD model, JAK inhibitors that look alike on paper had different effects on fibrosis, barrier function and inflammation, and methotrexate, a clinically used anti-inflammatory, reduced a fibrosis marker in a dose-dependent way in both Crohn’s patient models tested. “By leveraging patient-derived donor tissues, our disease platforms preserve the complex multiomic signatures and heterogeneous phenotypes seen in real-world clinical populations,” said Amar Sethi, M.D., Ph.D., Chief Scientific Officer of VivoSim Labs. “Crucially, we can now evaluate candidate compounds not only for primary disease endpoints like fibrosis and barrier repair, but also for target-specific pharmacodynamic biomarkers. This dual capability allows drug developers to confirm both functional human efficacy and underlying drug mechanism on the exact same platform before entering clinical trials.” About VivoSim Labs VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s cash on hand, revenue growth guidance and the Company’s progress in marketing contract research services using NAMs models to pharmaceutical companies. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. Contact(s): Investor Relations info@vivosim.ai VivoSim Labs, Inc.

很多人以为银屑病只是皮肤问题，涂点药膏就能好，其实不然。如果只治皮不治关节，等到关节变形、活动受限时，治疗难度会呈指数级上升。银屑病关节炎（PsA）是一种自身免疫性炎症疾病，约30%的银屑病患者会合并关节病变。近年来，随着生物制剂的突破，治疗手段已发生翻天覆地的变化，早期干预、达标治疗是关键。 一、传统治疗：基础但局限 轻度关节炎患者，医生通常会首先考虑非甾体抗炎药（NSAIDs），如布洛芬、双氯芬酸钠等，主要用于缓解疼痛和肿胀。对于轻中度病情，甲氨蝶呤（MTX）仍是全球公认的“锚定药物”，它能抑制免疫系统过度反应，保护关节结构。 需要注意的是，传统改善病情抗风湿药（DMARDs）起效较慢，通常需要4-12周才能显现疗效。且长期使用需监测肝肾功能和血常规，切勿自行增减剂量。如果传统治疗效果不佳，或病情进展迅速，应及时升级治疗方案，避免延误最佳治疗时机。 二、生物制剂：治疗的重大突破 这是近年来银屑病关节炎治疗领域最大的革新。生物制剂针对特定的炎症因子进行精准打击，起效快、疗效确切。 1. TNF-α抑制剂：如阿达木单抗、依那西普、英夫利西单抗。这类药物是老牌生物制剂，临床数据丰富，对皮肤和关节症状均有显著改善效果。2. IL-17抑制剂：如司库奇尤单抗、依奇珠单抗。这类药物在清除皮损和改善关节症状方面表现优异，尤其适合伴有中重度银屑病的关节炎患者。3. IL-12/23抑制剂：如乌司奴单抗，适合长期维持治疗。4. IL-23抑制剂：如古塞奇尤单抗、瑞莎珠单抗，给药频率低（如每8周或12周一次），患者依从性更好。 重要提醒：生物制剂属于处方药，必须在风湿免疫科或皮肤科医生指导下使用。使用前需筛查结核病、乙肝等潜在感染，治疗期间需定期复查。所有用药方案必须经专业医生评估后制定，禁止自行购买使用。 三、小分子药物：口服新选择 对于不愿注射生物制剂的患者，JAK抑制剂（如托法替布、乌帕替尼）提供了口服治疗方案。这类小分子药物作用机制明确，使用方便，但同样存在感染风险、血脂异常等潜在副作用，需严密监测。 四、非药物疗法：不可或缺的辅助 药物治疗是核心，但生活方式的调整同样关键。 物理治疗：针对性的康复训练有助于维持关节功能，防止肌肉萎缩。如手指操、踝泵运动等，建议在康复师指导下进行。- 心理调节：银屑病关节炎是身心疾病，焦虑、压力可能诱发或加重病情。保持乐观心态，必要时寻求心理咨询支持。- 饮食管理：建议采用抗炎饮食，多摄入富含Omega-3脂肪酸的食物（如深海鱼）、新鲜蔬果；限制高糖、高脂、红肉及酒精摄入，这些可能加重炎症反应。 五、患者自我监测要点 患者应学会记录“疾病活动度”，包括：- 早晨僵硬持续时间（超过30分钟提示活动期）- 关节肿痛数量- 皮肤银屑病面积指数（PASI）- 疲劳程度评分 每3个月复诊一次，医生会根据评估结果调整治疗方案，实现“临床缓解”或“低疾病活动度”的治疗目标。 【引用】[1] 中国银屑病诊疗指南（2023版）. 中华皮肤科杂志.[2] National Psoriasis Foundation. Clinical Guidelines for the Management of Psoriatic Arthritis.[3] American College of Rheumatology. 2018 Guideline for the Treatment of Psoriatic Arthritis.